Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Other Non-Current Liabilities (2021 - 2025)

Historic Other Non-Current Liabilities for Roivant Sciences (ROIV) over the last 5 years, with Q4 2025 value amounting to $677000.0.

  • Roivant Sciences' Other Non-Current Liabilities rose 12052.12% to $677000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $677000.0, marking a year-over-year increase of 12052.12%. This contributed to the annual value of $22000.0 for FY2025, which is 9911.75% down from last year.
  • As of Q4 2025, Roivant Sciences' Other Non-Current Liabilities stood at $677000.0, which was up 12052.12% from $170000.0 recorded in Q3 2025.
  • Roivant Sciences' 5-year Other Non-Current Liabilities high stood at $21.9 million for Q1 2022, and its period low was $22000.0 during Q1 2025.
  • In the last 5 years, Roivant Sciences' Other Non-Current Liabilities had a median value of $6.7 million in 2022 and averaged $7.1 million.
  • In the last 5 years, Roivant Sciences' Other Non-Current Liabilities surged by 16836.82% in 2022 and then tumbled by 9911.75% in 2025.
  • Quarter analysis of 5 years shows Roivant Sciences' Other Non-Current Liabilities stood at $8.2 million in 2021, then soared by 162.68% to $21.5 million in 2022, then plummeted by 79.38% to $4.4 million in 2023, then tumbled by 93.07% to $307000.0 in 2024, then surged by 120.52% to $677000.0 in 2025.
  • Its last three reported values are $677000.0 in Q4 2025, $170000.0 for Q3 2025, and $228000.0 during Q2 2025.